Cancer Vaccines Dogged by Misinformation; 867-5309 for Cancer; Bee Venom as Therapy?

Cancer vaccines could reshape cancer care — if misinformation does not derail the progress. (The Conversation)

Metformin once again has been linked to a lower risk of cancer, this time esophageal cancer. (JAMA Network Open)

The FDA approved nivolumab (Opdivo) plus chemotherapy for previously untreated stage III or IV classical Hodgkin lymphoma in adult and pediatric patients 12 years and older.

Even fairly modest weight loss can help reduce the risk of cancer. (Obesity)

An artificial intelligence-assisted analysis of lung cancers’ molecular profiles showed that 3% of tumors initially classified as primary cancers were in fact metastases, which would have changed management in 71% of the misdiagnosed cases. (JAMA Network Open)

A former research scientist at the University of Texas MD Anderson Cancer Center will spend time in prison after pleading guilty to stealing trade secrets to take to China. (Houston Public Media)

Johnson & Johnson has sued a former employee for massive and “malicious” trade secret theft, alleging she downloaded thousands of confidential documents to a personal device before leaving for a position with another drug company. (Fierce Pharma)

Cancer Support Community said it has taken over one of the world’s most widely recognized phone numbers: (CSC) 867-5309, popularized by Tommy Tutone’s 1981 hit song.

Pfizer said that the large improvement in progression-free survival with talazoparib (Talzenna) added to enzalutamide (Xtandi) in a phase III trial could portend earlier use of the PARP inhibitor in advanced prostate cancer.

Combination therapy including the multitargeted PIK3/mTOR signaling pathway inhibitor gedatolisib significantly improved progression-free survival versus fulvestrant in advanced hormone receptor-positive/HER2-negative breast cancer. (Journal of Clinical Oncology)

The geography of heavy cancer burden has shifted from urban to rural areas, as a multifactorial mortality gap continues to widen. (American Cancer Society)

Greenwich LifeSciences announced that the investigational immunotherapy agent GLSI-100 reduced the risk of recurrence in non-HLA-A*02 breast cancer as compared with historical data.

Second-line treatment with the CDK4 inhibitor atirmociclib plus fulvestrant reduced the risk of disease progression or death by 40% versus a two-drug combination of either fulvestrant or everolimus plus exemestane in advanced/metastatic hormone receptor-positive/HER2-negative breast cancer previously treated with a CDK4/6 inhibitor, Pfizer announced.

Could bee venom have a role in treating cancer? (UCLA Health)

Women are more likely than men to survive cancer but have a greater risk of serious adverse events. (Journal of the National Cancer Institute)

Preclinical studies of a ready-to-use immunotherapy based on natural killer T cells has shown promise as a potentially more effective and less costly treatment for endometrial cancer as compared with conventional immunotherapy. (UCLA Health)

Despite omission from the newest U.S. dietary guidelines, public awareness of the link between alcohol and cancer has remained steady, according to a survey by the Annenberg Public Policy Center.

Sampling wastewater for evidence of a colon cancer biomarker could offer a cost-effective way to target screening for the cancer. (Journal of Epidemiology & Community Health)